Resumen de Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

Javier Sastre Valera, Guillem Argilés Martínez, Manuel Benavides Orgaz, Jaime Feliu Batlle, Pilar García Alfonso, Rocío García Carbonero, Cristina Grávalos Castro, Carmen Guillén Ponce, Carles Pericay Pijaume

• Colorectal cancer is one of the most common tumors worldwide and at least 50 % of patients with this disease develop metastases. In this setting, additional treatment options are needed for patients presenting disease progression after exhausting all standard therapies. Regorafenib is an orally administered multikinase inhibitor which has been shown to provide survival benefits to patients with metastatic colorectal cancer (mCRC). Although most adverse events (AEs) associated with regorafenib may resolve within the first 8 weeks of treatment, some of them may require dose reduction or treatment interruption. Overall, while remaining aware of the safety profile of regorafenib and how to manage the most common toxicities related to its use, this drug should be considered a new standard of care for patients with pretreated mCRC. This review addresses practical aspects of its use, such as dosing, patient monitoring, and management of the most common regorafenib-related AEs.